The Cigna Group (CI) Investor Day 2026 summary

Strategic vision and portfolio evolution

• The company has shifted its portfolio over the past decade, divesting non-core businesses and expanding specialty pharmacy, pharma services, and employer-sponsored healthcare, with a focus on complex care and reducing exposure to less competitive areas.

• The unified strategy centers on delivering personalization at scale, especially for those with complex healthcare needs, leveraging data, technology, and AI across three growth platforms: Specialty and Care, Pharmacy Benefit Services, and Cigna Healthcare.

• Specialty and Care now represents 37% of total earnings, up from 30% two years ago, with significant growth in the Select employer segment and expansion in the medical benefit specialty space.

• The company reaffirmed its 2026 financial outlook and has delivered 14% compounded EPS growth over the last 10 years, demonstrating resilience through industry disruptions.

• A $3 billion multi-year efficiency and modernization initiative, Accelerate to One, was announced to drive productivity and reinvest in growth.

Business segment performance and growth drivers

• Evernorth (60% of earnings) is split between Specialty and Care (37%) and Pharmacy Benefit Services (23%), with each segment having distinct growth drivers and mutually reinforcing capabilities.

• Specialty and Care is projected to contribute 37% of enterprise adjusted earnings in 2026, targeting 8%-12% annual earnings growth and over 40% of total earnings by 2030, driven by drug innovation, biosimilars, and expanded distribution.

• Pharmacy Benefit Services is transitioning to the Signature rebate-free model, aiming for 0%-4% annual growth, with 50% of members expected to be enrolled by 2028, focusing on transparency, predictability, and administrative fee-based earnings.

• Cigna Healthcare (40% of earnings) targets 6%-9% annual growth, with Select segment market share expected to reach 10% by 2030, leveraging integrated data, risk management, and personalized care models.

• All three segments operate in large, growing addressable markets, with secular tailwinds and opportunities for above-market growth through distinct capabilities.

Technology, AI, and clinical innovation

• The Health Intelligence Engine integrates data across medical, pharmacy, specialty, and behavioral health to drive actionable insights, personalization, and improved outcomes, especially for complex care.

• AI and digital tools have reduced customer service calls, accelerated specialty benefit reviews, and enabled proactive, personalized clinical interventions, such as the HealthSense platform for oncology patients.

• Strategic partnerships, such as with Sierra AI and OpenAI, accelerate AI-driven innovation in customer engagement and clinical support, compounding value through learning loops and context-rich data.

• Clinical programs, such as transplant case management and Therapeutic Resource Centers, have demonstrated significant cost reductions and improved outcomes for complex patients.

• AI is used to augment, not replace, clinical expertise, with robust governance and a focus on earlier identification, personalized support, and improved affordability at scale.